- Home
- ALEC vs WHWK Comparison
ALEC vs WHWK Comparison
Compare ALEC & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALEC | WHWK |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | 23 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.4M | 208.7M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALEC | WHWK |
|---|---|---|
| Price | $2.17 | $4.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $4.83 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 593.7K | 406.2K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $21,045,000.00 | N/A |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $29.87 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $1.57 |
| 52 Week High | $3.40 | $5.50 |
Technical Indicators
Market Signals| Indicator | ALEC | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 44.57 | 58.36 |
| Support Level | $1.93 | $3.48 |
| Resistance Level | $2.64 | $5.50 |
| Average True Range (ATR) | 0.16 | 0.41 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 41.10 | 55.36 |
Price Performance
Historical ComparisonAbout ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.